Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue.

Three 18F labeled fluoronitroimidazoles have been prepared as potential in vivo markers of hypoxic cells in tumors, and ischemic areas of the heart and brain. 1-(2-Nitroimidazolyl)-3-[18F]fluoro-2-hydroxypropanol (18F]fluoro-normethoxymisonidazole) 4, 1-(2-[18F]fluoroethyl)-2-nitroimidazole 7, and 1-(2-[18F]-fluoroethyl)-2-methyl-5-nitroimidazole ([18F]fluoro-norhydroxymetronidazole) 10 were prepared in average radiochemical yields of less than 1%, 23% and 15-43% (8% at the no carrier-added level) respectively at end-of-synthesis. The in vivo biodistribution in rats was determined for each of the 18F labeled fluoronitroimidazoles. At 1 and 3 h after administration, the tissue distribution of each of the 18F labeled nitroimidzaoles was quite uniform and consistent with that of nitroimidazoles previously studied. These results suggest the need for a suitable animal model to evaluate their potential as in vivo markers of hypoxic tissue in the brain.

[1]  Chapman Jd,et al.  Hypoxic sensitizers--implications for radiation therapy. , 1979 .

[2]  G. Adams.  Chemical radiosensitization of hypoxic cells. , 1973, British Medical Bulletin.

[3]  I. Flockhart,et al.  Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. , 1978, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  J. Brown,et al.  Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. , 1980, Radiation research.

[5]  C. Koch,et al.  Binding of misonidazole to EMt6 and V79 spheroids. , 1982, International journal of radiation oncology, biology, physics.

[6]  J. D. Chapman,et al.  Binding of 14C-misonidazole to hypoxic cells in V79 spheroids. , 1982, British Journal of Cancer.

[7]  J. D. Chapman,et al.  Synthesis and in vivo studies of the radiosensitizer 4-[82Br]bromomisonidazole. , 1983, International journal of nuclear medicine and biology.

[8]  R. Blasberg,et al.  Regional [14C]misonidazole distribution in experimental RT-9 brain tumors. , 1983, Cancer research.

[9]  J. D. Chapman,et al.  Intracellular localization of radioactively labeled misonidazole in EMT-6-tumor cells in vitro. , 1982, International journal of radiation oncology, biology, physics.

[10]  P. Jerabek,et al.  An improved [18O]water target for [18F]fluoride production. , 1985, The International journal of applied radiation and isotopes.

[11]  R. Ings,et al.  The metabolism of metronidazole (1-2'-hydroxyethyl-2-methyl-5-nitroimidazole). , 1966, Biochemical pharmacology.

[12]  G. Lancini,et al.  The Ionization Constants of Some Imidazoles , 1964 .

[13]  J. D. Chapman,et al.  A marker for hypoxic cells in tumours with potential clinical applicability. , 1981, British Journal of Cancer.

[14]  K. Krohn,et al.  Bromomisonidazole: synthesis and characterization of a new radiosensitizer. , 1982, Radiation research.